MARKET

BYSI

BYSI

BeyondSpring
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.70
-4.88
-18.36%
After Hours: 21.75 +0.05 +0.23% 17:48 08/05 EDT
OPEN
25.92
PREV CLOSE
26.58
HIGH
26.01
LOW
21.30
VOLUME
11.74M
TURNOVER
--
52 WEEK HIGH
30.00
52 WEEK LOW
8.90
MARKET CAP
848.61M
P/E (TTM)
-11.4803
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 9h ago
26 Stocks Moving in Thursday's Pre-Market Session
Gainers
Benzinga · 10h ago
--Evercore ISI Adjusts BeyondSpring's Price Target to $95 From $30, Keeps Outperform Rating
MT Newswires · 14h ago
Hot Stocks: Hotels/airlines slip on COVID worries; BYSI skyrockets; ZY plunges; SPT sets new high; MRCY hits fresh low
COVID concerns claimed more victims on Wednesday. Hospitality and airline stocks lost ground during the session as worries about renewed pandemic restrictions weighed on those sectors. The retreat impacted stocks
Seekingalpha · 1d ago
NVAX, CDLX, ONE among midday movers
Gainers: BeyondSpring BYSI +156%. OneSmart International Education (NYSE:ONE) +72%. AeroCentury (NYSE:ACY) +40%. Robinhood Markets HOOD +37%. eXp World Holdings EXPI +34%. Atomera Incorporated ATOM +27%. Bit Digital BTBT +24%. Novavax (NASDAQ:NVAX) +21%. C...
Seekingalpha · 1d ago
BYSI Stock: The Huge Cancer News Sending BeyondSpring Skyrocketing Today
Investor Place · 1d ago
Sector Update: Health Care Stocks Unable to Sustain Midday Rise After Biotechs Fade Late
MT Newswires · 1d ago
Why BeyondSpring's Stock Is Rallying Today
BeyondSpring Inc. (NASDAQ: BYSI) shares are trading higher after the company announced results from its DUBLIN-3 trial of plinabulin in combination with docetaxel for non-small cell lung cancer, which showed the study met its primary endpoint and key secon...
Benzinga · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BYSI. Analyze the recent business situations of BeyondSpring through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BYSI stock price target is 61.60 with a high estimate of 100.00 and a low estimate of 37.00.
EPS
Institutional Holdings
Institutions: 74
Institutional Holdings: 7.21M
% Owned: 18.45%
Shares Outstanding: 39.11M
TypeInstitutionsShares
Increased
28
1.46M
New
15
741.98K
Decreased
13
349.60K
Sold Out
12
965.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.74%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Huang Lan
Chief Financial Officer
Elizabeth Czerepak
Chief Operating Officer
Richard Daly
Executive Vice President/Director
Ramon Mohanlal
Chief Scientific Officer
G. Kenneth Lloyd
Other
Gordon Schooley
Director
Brendan Delaney
Director
Ravindra Majeti
Independent Director
Patrick Fabbio
Independent Director
Matthew Kirkby
Independent Director
Quanqi Song
Independent Director
Jeffrey Vacirca
Independent Director
Yanbin Xie
Independent Director
Daniel Zabrowski
Independent Director
Ying Zhao
No Data
About BYSI
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology cancer therapies. The Company’s lead product Plinabulin, is being studied in late-stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company's product, Plinabulin, is a marine-derived small-molecule with a range of biological activities. Plinabulin targets cells in the tumor vasculature resulting in selective anti-tumor activity. Plinabulin has also demonstrated a range of immuno-stimulatory effects, including stimulating the maturation of dendritic cells, increasing cytokine secretion, downregulating inhibitory T-cells, and stimulating tumor-antigen-specific T-cell activation.

Webull offers kinds of Beyondspring Inc stock information, including NASDAQ:BYSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BYSI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BYSI stock methods without spending real money on the virtual paper trading platform.